Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01533376 · ClinicalTrials.gov registry record · Phase 1
Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol
A Phase 1 study, sponsored by Wills Eye.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01533376: Clinical Trial Phase 1 study, sponsored by Wills Eye.
NCT01533376 is a Phase 1 study that was terminated before completion, run by Wills Eye. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01533376, a Phase 1 study, was terminated before completion, sponsored by Wills Eye.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Primary Objective: • To assess the possible utility of topical timolol in the management of port-wine mark (PWM) in Sturge-Weber syndrome in children.
Primary Outcome
Changes of color and size of PWM at treatment site will determine efficacy of the topical timolol.
Interventions
- DRUG Timolol
- DRUG Preservative free artificial tear gel.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-02 |
| Est. Completion | 2019-02 |
| Phase | Phase 1 |
Why NCT01533376 stopped before completion
NCT01533376 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Timolol is the first listed.
NCT01533376 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01533376 about?
NCT01533376 is a clinical study titled "Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol". Primary Objective: • To assess the possible utility of topical timolol in the management of port-wine mark (PWM) in Sturge-Weber syndrome in children.
What is the current status of trial NCT01533376?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2012-02. Estimated completion is 2019-02.
What interventions are being tested in trial NCT01533376?
The interventions under investigation include: Timolol (DRUG), Preservative free artificial tear gel. (DRUG).
Who is sponsoring clinical trial NCT01533376?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01533376's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia